ArticleFrontiers in oncology2025
Ectopic breast fibroadenoma of the vulva: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vulvar ectopic breast fibroadenoma (EBF) is an exceptionally rare benign neoplasm that lacks distinctive clinical or radiological features rendering pre-operative differentiation from other vulvar masses challenging. Definitive diagnosis requires histopathological confirmation. Two non-exclusive histogenetic hypotheses have been proposed: (1) derivation from ectopic breast tissue along the embryonic "milk line," (2) origin from hormonally responsive anogenital mammary-like glands with latent potential for benign or malignant transformation. Case presentation: A 41-year-old woman presented with an incidentally discovered, slowly enlarging, painless right vulvar mass. Ultrasonography revealed a well-circumscribed hypoechoic nodule. Complete surgical excision was performed, and histopathological evaluation-including immunohistochemistry for estrogen receptor, progesterone receptor, GATA3, and p63-confirmed ectopic breast fibroadenoma. No recurrence was detected at 3-month follow-up. Conclusion: Despite its rarity, vulvar EBF must be considered in the differential diagnosis of vulvar masses in reproductive-age women. En-bloc excision is curative; however, long-term surveillance is warranted to monitor for hormone-driven recurrence or malignant evolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.